Ascend specializes in the manufacturing of adeno-associated virus (AAV) gene therapies, providing tailored support throughout the pre-clinical and clinical development stages. The company addresses the need for scalable and efficient production processes, enabling partners to deliver life-changing therapies to patients more quickly and affordably.
Funding
$194.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Producing adeno-associated virus (AAV) gene therapies at scale is challenging, often resulting in bottlenecks during pre-clinical and clinical development. Inefficient manufacturing processes can delay the delivery of life-changing therapies to patients and increase costs.
Solution
Ascend specializes in providing tailored support for AAV gene therapy manufacturing throughout the pre-clinical and clinical development stages. The company focuses on scalable and efficient production processes to enable partners to deliver therapies to patients more quickly and affordably. Ascend offers a flexible AAV manufacturing platform and a suite of analytical capabilities to meet the specific needs of each project. By acting as a thought partner, Ascend helps its customers navigate the complexities of AAV development and manufacturing.
Target Audience
Ascend's primary customers are biotechnology and pharmaceutical companies developing AAV gene therapies, particularly those in pre-clinical and clinical stages.
Features
- Scalable AAV manufacturing platform designed to support projects from pre-clinical to clinical stages
- Tailored services to fit every stage of the AAV development cycle
- World-class analytical capabilities for comprehensive AAV characterization
- Expertise in balancing quality and yield to optimize production processes
- Enabling technologies to adapt the platform to specific process needs
- Bioreactor runs up to 200L